Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
Other Sizes |
|
Purity: ≥98%
TAK1/MAP4K2 inhibitor 1 is a novel, potent dual TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2) inhibitor, with IC50s of 41.1 nM and 18.2 nM, respectively. It possesses good pharmacokinetic properties that will enable their use in pharmacological studies in vivo. A 2.4 Å cocrystal structure of TAK1 in complex with 1 confirms that the activation loop of TAK1 assumes the DFG-out conformation characteristic of type II inhibitors.
ln Vivo |
The intermediate terminal elimination half-life of TAK1/MAP4K2 inhibitor 1 (1 mg/kg, i.v.) in mice is 2.94 hours [1].
|
---|---|
References |
[1]. Tan L, et al. Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96.
|
Molecular Formula |
C29H31N6O2F3
|
---|---|
Molecular Weight |
552.59064
|
CAS # |
1315330-11-0
|
SMILES |
CC(N1)=CC2=C1N=CN=C2OC3=C(C)C=CC(C(NC4=CC=C(CN5CCN(CC)CC5)C(C(F)(F)F)=C4)=O)=C3
|
Synonyms |
TAK1/MAP4K2 inhibitor 1; TAK 1/MAP4K2 inhibitor 1; TAK-1/MAP4K2 inhibitor 1
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~50 mg/mL (~90.48 mM)
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8097 mL | 9.0483 mL | 18.0966 mL | |
5 mM | 0.3619 mL | 1.8097 mL | 3.6193 mL | |
10 mM | 0.1810 mL | 0.9048 mL | 1.8097 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Compound1is a type II inhibitor.J Med Chem. 2015 Jan 8;58(1):183-96. th> |
---|
Evaluation of the ability of compounds to inhibit IL-1α, LPS, or CL097-induced phosphorylation of p105, p38, and JNK in several cell types.J Med Chem. 2015 Jan 8;58(1):183-96. td> |
Evaluation of signaling following depletion of MAP4Ks by siRNA and evaluation of the ability of selective MAP4K2 inhibitors16and17to inhibit signaling in wild-type and TAK1-null MEF cells.J Med Chem. 2015 Jan 8;58(1):183-96. td> |